Revolution Medicines Stock Fundamentals
| RVMD Stock | USD 57.50 0.75 1.32% |
Revolution Medicines fundamentals help investors to digest information that contributes to Revolution Medicines' financial success or failures. It also enables traders to predict the movement of Revolution Stock. The fundamental analysis module provides a way to measure Revolution Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revolution Medicines stock.
At present, Revolution Medicines' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 79.4 M, whereas Depreciation And Amortization is forecasted to decline to about 6.5 M. Revolution | Select Account or Indicator |
Revolution Medicines Company Return On Equity Analysis
Revolution Medicines' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Revolution Medicines Return On Equity | -0.47 |
Most of Revolution Medicines' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revolution Medicines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Revolution Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Revolution Medicines has a Return On Equity of -0.4718. This is 98.03% lower than that of the Biotechnology sector and 98.71% lower than that of the Health Care industry. The return on equity for all United States stocks is 52.19% higher than that of the company.
Revolution Medicines Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Revolution Medicines's current stock value. Our valuation model uses many indicators to compare Revolution Medicines value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Revolution Medicines competition to find correlations between indicators driving Revolution Medicines's intrinsic value. More Info.Revolution Medicines is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Revolution Medicines' Return On Equity is projected to increase based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Revolution Medicines by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Revolution Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revolution Medicines' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revolution Medicines could also be used in its relative valuation, which is a method of valuing Revolution Medicines by comparing valuation metrics of similar companies.Revolution Medicines is currently under evaluation in return on equity category among its peers.
Revolution Medicines Current Valuation Drivers
We derive many important indicators used in calculating different scores of Revolution Medicines from analyzing Revolution Medicines' financial statements. These drivers represent accounts that assess Revolution Medicines' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Revolution Medicines' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 2.6B | 1.8B | 1.9B | 3.2B | 3.4B | |
| Enterprise Value | 1.7B | 2.6B | 1.8B | 1.8B | 2.6B | 1.4B |
Revolution Medicines ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Revolution Medicines' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Revolution Medicines' managers, analysts, and investors.Environmental | Governance | Social |
Revolution Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (845.95) % | ||||
| Current Valuation | 8.08 B | ||||
| Shares Outstanding | 168.22 M | ||||
| Shares Owned By Insiders | 2.13 % | ||||
| Shares Owned By Institutions | 97.87 % | ||||
| Number Of Shares Shorted | 18.14 M | ||||
| Price To Book | 6.09 X | ||||
| Price To Sales | 12,866 X | ||||
| Revenue | 11.58 M | ||||
| Gross Profit | (217.69 M) | ||||
| EBITDA | (430.58 M) | ||||
| Net Income | (436.37 M) | ||||
| Cash And Equivalents | 461.43 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 87.94 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 9.34 X | ||||
| Cash Flow From Operations | (350.57 M) | ||||
| Short Ratio | 14.94 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 71.43 | ||||
| Number Of Employees | 490 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 9.55 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 1.74 B | ||||
| Net Asset | 2.06 B |
About Revolution Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revolution Medicines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revolution Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revolution Medicines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -54.6 M | -51.8 M | |
| Total Revenue | 11.6 M | 11 M | |
| Cost Of Revenue | 411.2 M | 431.8 M | |
| Stock Based Compensation To Revenue | 5.33 | 5.60 | |
| Sales General And Administrative To Revenue | 6.53 | 6.86 | |
| Research And Ddevelopement To Revenue | 36.54 | 38.37 | |
| Capex To Revenue | 0.67 | 0.70 | |
| Revenue Per Share | 0.10 | 0.10 | |
| Ebit Per Revenue | (42.07) | (39.97) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:Check out Revolution Medicines Piotroski F Score and Revolution Medicines Altman Z Score analysis. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.005 | Quarterly Revenue Growth (0.95) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.